Joseph Truitt
Vermögen: 9 570 $ am 31.05.2026
Vermögen: 9 570 $ am 31.05.2026
Joseph Truitt is Chief Executive Officer & Director at iECURE, Inc. since 2021.
Mr. Truitt is Chairman at Larimar Therapeutics, Inc. since 2020.
Mr. Truitt is Director at Code Biotherapeutics, Inc. since 2020.
Former roles include Chief Executive Officer & Director at BioSpecifics Technologies Corp.
in 2020.
President, Chief Executive Officer & Director at Achillion Pharmaceuticals, Inc. from 2018 to 2020.
Vice President-Sales & Operations at Johnson & Johnson in 2006.
Vice President-Sales & Operations at OraPharma, Inc. in 2002.
VP-Business Development & Product Strategy at Lev Pharmaceuticals, Inc. from 2007 to 2008.
Education includes undergraduate studies at LaSalle University and an MBA from St. Joseph's University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.05.2026 | 2’750 ( 0% ) | 9 570 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Vorsitzender | 28.05.2020 |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Direktor/Vorstandsmitglied | 01.12.2020 |
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage biotechnology company that develops in-vivo gene insertion/editing therapies to treat rare liver disorders | Vorstandsvorsitzender | 01.03.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
| BIOSPECIFICS TECHNOLOGIES CORP. | Vorstandsvorsitzender | 02.12.2020 |
| ACHILLION PHARMACEUTICALS, INC. | Vorstandsvorsitzender | 28.01.2020 |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products for the treatment of inflammatory diseases | Corporate Officer/Principal | 01.12.2008 |
| JOHNSON & JOHNSON | Geschäftsführer | 01.07.2006 |
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces drugs for oral diseases | Geschäftsführer | 01.01.2002 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 10 |
|---|---|
Johnson & Johnson
Johnson & Johnson Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in health care products | Health Technology |
BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. Pharmaceuticals: MajorHealth Technology Develops injectable collagenase clostridium histolyticum (CCH) for multiple indications | Health Technology |
OraPharma, Inc.
OraPharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and produces drugs for oral diseases | Health Technology |
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
LaSalle University
LaSalle University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
St. Joseph's University
St. Joseph's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lev Pharmaceuticals, Inc.
Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products for the treatment of inflammatory diseases | Health Technology |
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company focused on developing treatments for complex rare diseases | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
IEcure, Inc.
IEcure, Inc. BiotechnologyHealth Technology Operates as a a clinical-stage biotechnology company that develops in-vivo gene insertion/editing therapies to treat rare liver disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen